Bruno C. Jham, D.D.S., M.S., Ph.D.

Midwestern University
College of Dental Medicine – Illinois
Auditorium Building 594
555 31st St. Downers Grove, IL 60515 

Office: (630) 515-7469


D.D.S. Dentistry Federal University of Diamantina 2001
M.S. Oral Medicine Federal University of Minas Gerais 2006
Certificate Oral and Maxillofacial Pathology University of Maryland, Baltimore 2009
Ph.D.  Oral and Experimental Pathology University of Maryland, Baltimore  2010


Oral squamous cell carcinoma (OSCC) is the most frequent malignant tumor in the oral cavity. Each year, 35,000 new cases of OSCC are diagnosed in the United States, with 8,000 deaths. Despite recent advances in the pathogenesis of OSCC, survival rates of patients have remained practically unaltered over the past 50 years. The elucidation of the molecular pathways involved in the initiation and progression of OSCC could lead to the identification of biomarkers that could ultimately serve as molecular-based therapeutic targets in the treatment of OSCC and, ultimately, reduce patient morbidity and mortality.

Tumor angiogenesis (the formation of new blood vessels) is required for delivery of oxygen, nutrients, and growth factors to malignant cells, thus being necessary to stimulate primary and metastatic tumor growth. Angiogenesis is a hallmark and important player in the development and progression of several cancers, including OSCC. Indeed, up to 90% of OSCC express angiogenic factors, such as vascular endothelial growth factor and its respective receptors. My current interests relate to the identification and characterization of a novel angiogenic molecules involved in the development and progression of OSCC.

The PI3K/Akt/mTOR pathway regulates multiple cellular processes such as cell proliferation, growth, apoptosis and survival, and is frequently altered event in OSCC. One of my current interests is to study this pathway in OSCC and other diseases that affect the head and neck complex, such as odontogenic cysts and tumors, to further our understanding of the biology of these conditions and possibly lead to the development of novel therapeutic strategies. 

Selected Publications (See PubMed results)

The Akt/mTOR pathway is activated in verrucous carcinoma of the oral cavity.  Chaisuparat R, Limpiwatana S, Kongpanitkul S, Yodsanga S, Jham BC. J Oral Pathol Med. 2016 [In press]

Activation of the Akt/mTOR pathway in dentigerous cysts, odontogenic keratocysts, and ameloblastomas. Chaisuparat R, Yodsanga S, Montaner S, Jham BC. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013 Sep;116(3):336-42

Expression of midkine in ameloblastomas and its correlation with clinicopathologic parameters. Scheper MA, Duarte EC, Intapa C, Zhang M, Nascimento LM, Almeida TP, Gomes AC, Song S, Chaisuparat R, Batista AC, Jham BC. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012 Oct;114(4):497-502

Midkine expression in oral squamous cell carcinoma and leukoplakia. Jham BC, Costa NL, Silva JM, de Miranda AC, Oliveira JC, Silva TA, Batista AC. J Oral Pathol Med. 2012 Jan;41(1):21-6.

Amplification of the angiogenic signal through the activation of the TSC/mTOR/HIF axis by the KSHV vGPCR in Kaposi's sarcoma. Jham BC, Ma T, Hu J, Chaisuparat R, Friedman ER, Pandolfi PP, Schneider A, Sodhi A, Montaner S. PLoS One. 2011 Apr 29;6(4):e19103

Angiopoietin-like 4: a novel molecular hallmark in oral Kaposi's sarcoma. Hu J, Jham BC, Ma T, Friedman ER, Ferreira L, Wright JM, Accurso B, Allen CM, Basile JR, Montaner S. Oral Oncol. 2011 May;47(5):371-5

Viral G protein-coupled receptor up-regulates Angiopoietin-like 4 promoting angiogenesis and vascular permeability in Kaposi's sarcoma. Ma T, Jham BC, Hu J, Friedman ER, Basile JR, Molinolo A, Sodhi A, Montaner S. Proc Natl Acad Sci U S A. 2010 Aug 10;107(32):14363-8.